New drug cocktail aims to fight advanced skin cancer

NCT ID NCT07099430

Recruiting now Disease control Sponsor: Nanjing Leads Biolabs Co.,Ltd Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called LBL-024, alone or combined with LBL-007 or toripalimab, in 200 people with advanced melanoma. The goal is to see if these treatments are safe and can shrink tumors. Participants receive the drugs through an IV, and doctors monitor side effects and how long the cancer stays under control.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: LBL-024 (a drug), LBL-007 (a drug), and toripalimab (a drug)
What this could lead to: If successful, this could point toward new treatment options for advanced melanoma, potentially shrinking tumors or slowing disease progression.
What could go wrong: This is an early-phase trial (Phase Ib/II) with only 200 participants, so results may not apply to all patients. Side effects are possible, and the drugs may not work as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cutaneous melanoma melanoma metastatic melanoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MELANOMA

Contacts and locations

Locations

Dermatology Hospital of Southern Medical University
NOT_YET_RECRUITING

Guangzhou, Guangdong, 510080, China
Fudan University Shanghai Cancer Center
NOT_YET_RECRUITING

Shanghai, Shanghai Municipality, 200032, China
Fujian Cancer Hospital
RECRUITING

Fuzhou, Fujian, 350014, China
Guangxi Medical University Cancer Hospital
RECRUITING

Nanning, Guangxi, 530200, China
Nanjing Drum Tower Hospital
RECRUITING

Nanjing, Jiangsu, 210009, China
Shandong Cancer Hospital
RECRUITING

Jinan, Shandong, 250117, China
Shanxi Bethune Hospital
RECRUITING

Taiyuan, Shanxi, 030032, China
Sun Yat-sen University Cancer Center
RECRUITING

Guangzhou, Guangdong, 510060, China
The First Hospital of Jilin University
NOT_YET_RECRUITING

Changchun, Jilin, 130021, China
The Second Affiliated Hospital of Xi'an Jiaotong University
NOT_YET_RECRUITING

Xi’an, Shanxi, 710004, China
Tianjin Medical University Cancer Institute &Hospital
NOT_YET_RECRUITING

Tianjin, Tianjin Municipality, 300060, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
RECRUITING

Wuhan, Hubei, 430022, China
West China Hospital of Sichuan University
RECRUITING

Chengdu, Sichuan, 610041, China
Yunnan Cancer Hospital
RECRUITING

Kunming, Yunnan, 650118, China
Zhejiang Cancer Hospital
NOT_YET_RECRUITING

Hangzhou, Zhejiang, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.